Back to Newsroom

CombiMatrix Reports Preliminary Growth in Prenatal Microarray Testing Volumes of 71% and 64% for the Third Quarter and Year-to-Date, Respectively

IRVINE, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that it expects to report record volumes of prenatal testing in the third quarter and nine months ended September 30, 2014. Preliminary growth rates of 71 percent and 64 percent are estimated for billable prenatal tests in the third quarter and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company’s strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care.

Click here to read more